Biological therapy for systemic vasculitis: A systematic review

Seminars in Arthritis and Rheumatism

Volumn 43, Issue 4, 2014, Pages 542-557

  Silva Fernández, Lucía ^a   Loza, Estíbaliz ^b   Martínez Taboada, Víctor M ^c   Blanco, Ricardo ^c   Rúa Figueroa, Íñigo ^d   Pego Reigosa, José María ^e   Muñoz Fernández, Santiago ^f  

^a HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^b Institute for Health   (Spain)

^c HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^d HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^e UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

^f HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

Author keywords

ANCA associated vasculitis; Biological therapy; Large vessel vasculitis; Systematic review

Indexed keywords

ANCA-ASSOCIATED VASCULITIS; BIOLOGICAL THERAPY; LARGE VESSEL VASCULITIS; SYSTEMATIC REVIEW;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BIOLOGICAL PRODUCTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; REMISSION INDUCTION; SYSTEMIC VASCULITIS; TREATMENT OUTCOME;

EID: 84894904450     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2013.07.010     Document Type: Article

References (118)

1. Reinhold-Keller E., Herlyn K., Wagner-Bastmeyer R., Gross W.L. Stable incidence of primary systemic vasculitides over five years: results from the German vasculitis register. Arthritis Rheum 2005, 53:93-99.
2. Jennette J.C., Falk R.J., Andrassy K., Bacon P.A., Churg J., Gross W.L., et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994, 37:187-192.
3. Sorensen S.F., Slot O., Tvede N., Petersen J. A prospective study of vasculitis patients collected in a five year period: evaluation of the Chapel Hill nomenclature. Ann Rheum Dis 2000, 59:478-482.
4. Basu N., Watts R., Bajema I., Baslund B., Bley T., Boers M., et al. EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Ann Rheum Dis 2010, 69:1744-1750.
5. Hoffman G.S., Kerr G.S., Leavitt R.Y., Hallahan C.W., Lebovics R.S., Travis W.D., et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992, 116:488-498.
6. Gayraud M., Guillevin L., le Toumelin P., Cohen P., Lhote F., Casassus P., et al. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 2001, 44:666-675.
7. Reinhold-Keller E., Beuge N., Latza U., de Groot K., Rudert H., Nolle B., et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000, 43:1021-1032.
8. Oxford Centre for Evidence-based Medicine. Levels of evidence. Available at: [accessed 19.06.13]. http://www.cebm.net/?o=1025.
9. Martinez-Taboada V.M., Rodriguez-Valverde V., Carreno L., Lopez-Longo J., Figueroa M., Belzunegui J., et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 2008, 67:625-630.
10. Hoffman G.S., Cid M.C., Rendt-Zagar K.E., Merkel P.A., Weyand C.M., Stone J.H., et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis a randomized trial. Ann Intern Med 2007, 146:621-630.
11. Stone J.H., Holbrook J.T., Marriott M.A., Tibbs A.K., Sejismundo L.P., Min Y.I., et al. Solid malignancies among patients in the Wegener's granulomatosis etanercept trial. Arthritis Rheum 2006, 54:1608-1618.
12. Specks U., Merkel P.A., Seo P., Spiera R.F., Langford C.A., Hoffman G.S., et al. Immunoglobulin concentrations and infection risk among patients with ANCA-associated vasculitis treated with rituximab or cyclophosphamide. Arthritis Rheum 2011, 63:S310-S311. [abstract].
13. Geetha D., Fervenza F. The efficacy of rituximab vs cyclophosphamide for treatment of renal disease in ANCA-associated vasculitis: the RAVE trial. Arthritis Rheum 2012, 64:S660. [abstract].
14. Miloslavsky E., Specks U., Stone J.H. Primary endpoint failure in the rituximab in ANCA-associated vasculitis trial. Arthritis Rheum 2012, 64:S707. RAVE/ITN Research Group, [abstract].
15. Stone J.H., Merkel P.A., Seo P., Spiera R., Langford C.A., Hoffman G.S., et al. Extended follow-up of treatment with rituximab versus cyclophosphamide for remission-induction of ANCA-associated vasculitis: which subsets are at greatest risk for Flare?. Arthritis Rheum 2011, 63:S946-S947. [abstract].
16. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005, 351-361. Wegener's Granulomatosis Etanercept Trial Research Group.
17. Silva F., Seo P., Schroeder D.R., Stone J.H., Merkel P.A., Hoffman G.S., et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term followup of a multicenter longitudinal cohort. Arthritis Rheum 2011, 63:2495-2503.
18. de Menthon M., Cohen P., Pagnoux C., Buchler M., Sibilia J., Detree F., et al. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clin Exp Rheumatol 2011, 29:S63-S71.
19. Jones R.B., Tervaert J.W., Hauser T., Luqmani R., Morgan M.D., Peh C.A., et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010, 363:211-220.
20. Stone J.H., Merkel P.A., Spiera R., Seo P., Langford C.A., Hoffman G.S., et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010, 363:221-232.
21. Guillevin L., Pagnoux C., Karras A., Khoutra C., Aumaitre O., Cohen P., et al. Rituximab verus azathioprine for maintenance in antineutrophil cytoplasmic antiboides (ANCA)-associated vasculitis. Arthritis Rheum 2012, 64:S706. [abstract].
22. Terrier B., Pagnoux C., Karras A., Khouatra C., Aumaitre O., Cohen P., et al. Rituximab versus azathioprine for maintenance in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (MAINRITSAN): follow up at 34 months. Ann Rheum Dis 2013, 72:124. [abstract].
23. Mariette X., Baron G., Hachulla E., DeBandt M., Larroche C., Puechal X., et al. Results of a randomized controlled study of adalimumab for steroid sparing in patients with giant-cell arteritis. Arthritis Rheum 2011, 63:S589. [abstract].
24. Jones R.B., Tervaert J.W., Hauser T., Luqmani R., Morgan M.D., Peh C.A., et al. Two year follow-up results from a randomised trial of rituximab versus cyclophosphamide for generalized ANCA-associated vasculitis: RITUXVAS. Arthritis Rheum 2010, 62:676. [abstract].
25. Smith K.G., Jones R.B., Burns S.M., Jayne D.R. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum 2006, 54:2970-2982.
26. Booth A., Harper L., Hammad T., Bacon P., Griffith M., Levy J., et al. Prospective study of TNF(alpha) blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 2004, 15:717-721.
27. Laurino S., Chaudhry A., Booth A., Conte G., Jayne D. Prospective study of TNFalpha blockade with adalimumab in ANCA-associated systemic vasculitis with renal involvement. Nephrol Dial Transplant 2010, 25:3307-3314.
28. Keogh K.A., Ytterberg S.R., Fervenza F.C., Carlson K.A., Schroeder D.R., Specks U. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006, 173:180-187.
29. Stone J.H., Uhlfelder M.L., Hellmann D.B., Crook S., Bedocs N.M., Hoffman G.S. Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum 2001, 44:1149-1154.
30. Kim S., Marigowda G., Oren E., Israel E., Wechsler M.E. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol 2010, 125:1336-1343.
31. Hoffman G.S., Merkel P.A., Brasington R.D., Lenschow D.J., Liang P. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 2004, 50:2296-2304.
32. Morgan M.D., Drayson M.T., Savage C.O., Harper L. Addition of infliximab to standard therapy for ANCA-associated vasculitis. Nephron Clin Pract 2011, 117:c89-c97.
33. Mansfield N., Hamour S., Habib A.M., Tarzi R., Levy J., Griffith M., et al. Prolonged disease-free remission following rituximab and low-dose cyclophosphamide therapy for renal ANCA-associated vasculitis. Nephrol Dial Transplant 2011, 26:3280-3286.
34. Dass S., Vital E., Pease C., Buch M., Martin M., Andrews J., et al. Rituximab provides stable long term resonses in ANCA associated vasculitis. Ann Rheum Dis 2011, 70:83. [abstract].
35. Cartin-Ceba R., Golbin J.M., Keogh K.A., Peikert T., Sanchez-Menendez M., Ytterberg S.R., et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center. Arthriits Rheum 2012, 64:3770-3778.
36. Smith R.M., Jones R.B., Guerry M.J., Laurino S., Catapano F., Chaudhry A., et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012, 64:3760-3769.
37. Roll P., Ostermeier E., Haubitz M., Lovric S., Unger L., Holle J., et al. Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a German Registry (GRAID). J Rheumatol 2012, 39:2153-2156.
38. Md Yusof M.Y., Vital E., Dass S., Pease C., Martin M., Savic S., et al. Safety of rituximab for remission maintenance in relapsing ANCA-associated vasculitis: repeat cycles on clinical relapse are associated with low rates of hypogammaglobulinaemia. Ann Rheum Dis 2013, 72:487. [abstract].
39. Langford C.A., Cuthbertson D., Hoffman G.S., Krischer J., McAlear C.A., Monach P.A., et al. An open-label trial of abatacept in mild relapsing granulomatosis with polyangiitis (Wegener's). Arthritis Rheum 2012, 64:S707. [abstract].
40. Herrmann K., Gross W.L., Moosig F. Extended follow-up after stopping mepolizumab in relapsing/refractory Churg-Strauss syndrome. Clin Exp Rheumatol 2012, 30:S62-S65.
41. Moosig F., Gross W.L., Herrmann K., Bremer J.P., Hellmich B. Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome. Ann Intern Med 2011, 155:341-343.
42. Booth A.D., Jayne D.R., Kharbanda R.K., McEniery C.M., Mackenzie I.S., Brown J., et al. Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. Circulation 2004, 109:1718-1723.
43. Eriksson P. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 2005, 257:540-548.
44. Venhoff V., Effelsberg N.M., Salzer U., Warnatz K., Peter H.H., Lebrecht D., et al. Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides. PLOS One 2012, 7:e37626.
45. Keogh K.A., Wylam M.E., Stone J.H., Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005, 52:262-268.
46. Stasi R., Stipa E., Del Poeta G., Amadori S., Newland A.C., Provan D. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford) 2006, 45:1432-1436.
47. Roccatello D., Baldovino S., Alpa M., Rossi D., Napoli F., Naretto C., et al. Effects of anti-CD20 monoclonal antibody as a rescue treatment for ANCA-associated idiopathic systemic vasculitis with or without overt renal involvement. Clin Exp Rheumatol 2008, 26:S67-S71.
48. Jones R.B., Ferraro A.J., Chaudhry A.N., Brogan P., Salama A.D., Smith K.G., et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009, 60:2156-2168.
49. Lovric S., Erdbruegger U., Kumpers P., Woywodt A., Koenecke C., Wedemeyer H., et al. Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients. Nephrol Dial Transplant 2009, 24:179-185.
50. Ramos-Casals M., Garcia-Hernandez F.J., de Ramon E., Callejas J.L., Martinez-Berriotxoa A., Pallares L., et al. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol 2010, 28:468-476.
51. Rhee E.P., Laliberte K.A., Niles J.L. Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin J Am Soc Nephrol 2010, 5:1394-1400.
52. Roccatello D., Sciascia S., Rossi D., Alpa M., Naretto C., Russo A., et al. Long-term effects of rituximab added to cyclophosphamide in refractory patients with vasculitis. Am J Nephrol 2011, 34:175-180.
53. Tony H.P., Burmester G., Schulze-Koops H., Grunke M., Henes J., Kotter I., et al. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther 2011, 13:R75.
54. Rees F., Yazdani R., Lanyon P. Long-term follow-up of different refractory systemic vasculitides treated with rituximab. Clin Rheumatol 2011, 30:1241-1245.
55. Sangle S.R., Hughes G.R., D'Cruz D.P. Infliximab in patients with systemic vasculitis that is difficult to treat: poor outcome and significant adverse effects. Ann Rheum Dis 2007, 66:564-565.
56. Josselin L., Mahr A., Cohen P., Pagnoux C., Guaydier-Souquieres G., Hayem G., et al. Infliximab efficacy and safety against refractory systemic necrotising vasculitides: long-term follow-up of 15 patients. Ann Rheum Dis 2008, 67:1343-1346.
57. Walsh M., Chaudhry A., Jayne D. Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). Ann Rheum Dis 2008, 67:1322-1327.
58. Aries P.M., Hellmich B., Voswinkel J., Both M., Nolle B., Holl-Ulrich K., et al. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 2006, 65:853-858.
59. Brihaye B., Aouba A., Pagnoux C., Cohen P., Lacassin F., Guillevin L. Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener's granulomatosis: a study on 8 patients. Clin Exp Rheumatol 2007, 25:S23-S27.
60. Garcia Hernandez F.J., Ocana Medina C., Gonzalez Leon R., Garrido Rasco R., Colorado Bonilla R., Castillo Palma M.J., et al. Rituximab for treatment of patients with systemic autoimmune diseases. Med Clin (Barc) 2007, 128:458-462.
61. Henes J.C., Fritz J., Koch S., Klein R., Horger M., Risler T., et al. Rituximab for treatment-resistant extensive Wegener's granulomatosis-additive effects of a maintenance treatment with leflunomide. Clin Rheumatol 2007, 26:1711-1715.
62. Sanchez-Cano D., Callejas-Rubio J.L., Ortego-Centeno N. Effect of rituximab on refractory Wegener granulomatosis with predominant granulomatous disease. J Clin Rheumatol 2008, 14:92-93.
63. Seo P., Specks U., Keogh K.A. Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations. J Rheumatol 2008, 35:2017-2023.
64. Taylor S.R., Salama A.D., Joshi L., Pusey C.D., Lightman S.L. Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis. Arthritis Rheum 2009, 60:1540-1547.
65. Martinez Del Pero M., Chaudhry A., Jones R.B., Sivasothy P., Jani P., Jayne D. B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study. Clin Otolaryngol 2009, 34:328-335.
66. Joshi L., Lightman S.L., Salama A.D., Shirodkar A.L., Pusey C.D., Taylor S.R. Rituximab in refractory ophthalmic Wegener's granulomatosis: PR3 titers may predict relapse, but repeat treatment can be effective. Ophthalmology 2011, 118:2498-2503.
67. Bartolucci P., Ramanoelina J., Cohen P., Mahr A., Godmer P., Le Hello C., et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 2002, 41:1126-1132.
68. Lamprecht P., Voswinkel J., Lilienthal T., Nolle B., Heller M., Gross W.L., et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) 2002, 41:1303-1307.
69. Lockwood C.M. Refractory Wegener's granulomatosis: a model for shorter immunotherapy of autoimmune diseases. J R Coll Physicians Lond 1998, 32:473-478.
70. Lockwood C.M., Thiru S., Stewart S., Hale G., Isaacs J., Wraight P., et al. Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies. QJM 1996, 89:903-912.
71. Cantini F., Niccoli L., Salvarani C., Padula A., Olivieri I. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum 2001, 44:2933-2935.
72. Seitz M., Reichenbach S., Bonel H.M., Adler S., Wermelinger F., Villiger P.M. Rapid induction of remission in large vessel vasculitis by IL-6 blockade: a case series. Swiss Med Wkly 2011, 141:w13156.
73. Molloy E.S., Langford C.A., Clark T.M., Gota C.E., Hoffman G.S. Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Ann Rheum Dis 2008, 67:1567-1569.
74. Mekinian A., Neel A., Sibilia J., Cohen P., Connault J., Lambert M., et al. Efficacy and tolerance of infliximab in refractory Takayasu arteritis: French multicentre study. Rheumatology (Oxford) 2012, 51:882-886.
75. Karageorgaki Z.T., Mavragani C.P., Papathanasiou M.A., Skopouli F.N. Infliximab in Takayasu arteritis: a safe alternative?. Clin Rheumatol 2007, 26:984-987.
76. Tesfa D., Ajeganova S., Hagglund H., Sander B., Fadeel B., Hafstrom I., et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum 2011, 63:2209-2214.
77. Lutalo P.M.K., Scott I.C., Sangle S., D'Cruz D.P. Rituximab in relapsing granulomatosis with polyangiitis (Wegener's granulomatosis): a case series. Arthritis Rheum 2011, 63:S925. [abstract].
78. Gatenby P., Cook M., Falk M., Karpe K., Singer R., Talaulikar G., et al. RTX as rescue therapy in ANCA- associated systemic vasculitis: a single centre experience. Clin Exp Immunol 2011, 164:55-56. [abstract].
79. Holle J.U., Dubrau C., Herlyn K., Heller M., Ambrosch P., Noelle B., et al. Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. Ann Rheum Dis 2012, 71:327-333.
80. Pullerits R., Ljevak M., Vikgren J., Bokarewa M. Off-trial evaluation of the B cell-targeting treatment in the refractory cases of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: long-term follow-up from a single centre. Scand J Immunol 2012, 76:411-420.
81. Roubaud-Baudron C., Pagnoux C., Meaux-Ruault N., Grasland A., Zoulim A., Leg J., et al. Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. J Rheumatol 2012, 39:125-130.
82. Wendt M., Gunnarsson I., Bratt J., Bruchfeld A. Rituximab in relapsing or refractory ANCA-associated vasculitis: a case series of 16 patients. Scand J Rheumatol 2012, 41:116-119.
83. Baslund B., Wiencke A.K., Rasmussen N., Faurschou M., Toft P.B. Treatment of orbital inflammation with rituximab in Wegener's granulomatosis. Clin Exp Rheumatol 2012, 30:S7-S10.
84. Lower E.E., Baughman R.P., Kaufman A.H. Rituximab for refractory granulomatous eye disease. Clin Ophthalmol 2012, 6:1613-1618.
85. Khan H., Bharadwaj A., Gendi N. Rituximab is an effective and safe treatment for treatment of refractory ANCA positive vasculitis-a single centre experience of six cases. Int J Rheum Dis 2012, 15:110. [abstract].
86. Knight A., Hallenberg H., Baecklund E. Successful maintenance treatment of granulomatosis polyangiitis (Wegener) with rituximab-a case series. Ann Rheum Dis 2012, 71:681. [abstract].
87. Azar L., Springer J., Xu M., Clark T.M., Langford C.A., Hoffman G.S. Long-term outcome of patients with granulomatosis with polyangiitis (Wegener's) treated with rituximab. Arthritis Rheum 2012, 64:S660-S661. [abstract].
88. Charles P., Neel A., Tieulie N., Hot A., Gregory P., Decaux O., et al. Rituximab as induction and maintenance therapies for ANCA-associated vasculitis: a multicentr retrospective study on 80 patients. Arthritis Rheum 2012, 64:S1004. [abstract].
89. Dubrau C., Arndt F., Gross W.L., Moosig F. Successful treatment of Churg-Strauss syndrome with rituximab. Arthritis Rheum 2012, 64:S1002-S1003. [abstract].
90. Schmidt J., Kermani T.A., Kirstin Bacani A., Crowson C.S., Matteson E.L., Warrington K.J. Tumor necrosis factor inhibitors in patients with Takayasu arteritis: experience from a referral center with long-term follow-up. Arthritis Rheum 2011, 63:S587. [abstract].
91. Unizony S., Arias-Urdaneta L., Miloslavsky E., Arvikar S., Khosroshahi A., Keroack B., et al. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res 2012, 64:1720-1729.
92. Salvarani C., Magnani L., Catanoso M., Pipitone N., Versari A., Dardani L., et al. Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology (Oxford) 2012, 51:151-156.
93. Cañas C., Izquierdo J.H., Bonilla F. Efficacy of anti-interleukin-6 receptor antibody (tocilizumab) in Colombian patients with Takayasu's arteritis. Ann Rheum Dis 2012, 71:681. [abstract].
94. Quartuccio L., Schiavon F., Zuliani F., Carraro V., Catarsi E., Tavoni A.G., et al. Long-term efficacy and improvement of health-related quality of life in patients with Takayasu's arteritis treated with infliximab. Clin Exp Rheumatol 2012, 30:922-928.
95. Tombetti E., Baldissera E., Franchini S., Aiello P., Motta F., Gulgielmi B., et al. Tocilizumab in refractory Takayasu's arteritis: 7 patients followe at a single Italian centre. Arthritis Rheum 2012, 64:S998. [abstract].
96. Tombetti E., Baldissera E., Bozzolo E., Franchini S., Sabbadini M.G. Treatment of refractory Takayasu arteritis with tocilizumab: seven Italian patients from a single referral center. Ann Rheum Dis 2013, 72:493. [abstract].
97. Tombetti E., Baldissera E., Franchini S., Motta F., Aiello P., Cavalli G., et al. Efficacy of anti-TNF therapy in 15 patients with refractory Takayasu's arteritis: long-term unicentric follow-up. Ann Rheum Dis 2012, 71:226. [abstract].
98. Comarmond C., Plaisier E., Dahan K., Mirault T., Emmerich J., Amoura Z., et al. Anti TNF-alpha in refractory Takayasu's arteritis: cases series and review of the literature. Autoimmun Rev 2012, 11:678-684.
99. Efficacy study of two treatments in the remission of vasculitis (MAINRITSAN). ClinicalTrials.gov identifier. Available at: [accessed 24.06.13]. http://www.clinicaltrials.gov/ct2/show/NCT00748644?term=mainritsan&rank=1.
100. Fauci A.S., Haynes B.F., Katz P., Wolff S.M. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983, 98:76-85.
101. Eriksson P., Jacobsson L., Lindell A., Nilsson J.A., Skogh T. Improved outcome in Wegener's granulomatosis and microscopic polyangiitis? A retrospective analysis of 95 cases in two cohorts. J Intern Med 2009, 265:496-506.
102. Stratta P., Marcuccio C., Campo A., Sandri L., Messuerott A., Colla L., et al. Improvement in relative survival of patients with vasculitis: study of 101 cases compared to the general population. Int J Immunopathol Pharmacol 2008, 21:631-642.
103. Ishikawa K., Maetani S. Long-term outcome for 120 Japanese patients with Takayasu's disease. Clinical and statistical analyses of related prognostic factors. Circulation 1994, 90:1855-1860.
104. US Food and Drug Administration. FDA approves rituxan to treat two rare disorders. Available at: [accessed September 2012]. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm251946.htm.
105. European Medicines Agency. http://www.ema.europa.eu/ema.
106. Popa C., Leandro M.J., Cambridge G., Edwards J.C.W. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology (Oxford) 2007, 46:626-630.
107. van Vollenhoven R.F., Emery P., Bingham C.O., Keystone E.C., Fleischmann R., Septimo A. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 2010, 37:558-567.
108. Gottenberg J.E., Ravaud P., Bardin T., Cacoub P., Cantagrel A., Combe B., et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum 2010, 62:2625-2632.
109. Chan A.T., Flossmann O., Mukhtyar C., Jayne D.R., Luqmani R.A. The role of biologic therapies in the management of systemic vasculitis. Autoimmun Rev 2006, 5:273-278.
110. Huugen D., Xiao H., van Esch A., Falk R.J., Peutz-Kootstra C.J., Buurman W.A., et al. Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha. Am J Pathol 2005, 167:47-58.
111. Noronha I.L., Kruger C., Andrassy K., Ritz E., Waldherr R. In situ production of TNF-alpha, IL-1 beta and IL-2R in ANCA-positive glomerulonephritis. Kidney Int 1993, 43:682-692.
112. Kahn J.E., Grandpeix-Guyodo C., Marroun I., Catherinot E., Mellot F., Roufosse F., et al. Sustained response to mepolizumab in refractory Churg-Strauss syndrome. J Allergy Clin Immunol 2010, 125:267-270.
113. Giavina-Bianchi P., Agondi R., Kalil J. One year administration of anti-IgE to a patient with Churg-Strauss syndrome. Int Arch Allergy Immunol 2008, 146:176.
114. Giavina-Bianchi P., Giavina-Bianchi M., Agondi R., Kalil J. Administration of anti-IgE to a Churg-Strauss syndrome patient. Int Arch Allergy Immunol 2007, 144:155-158.
115. Pabst S., Tiyerili V., Grohe C. Apparent response to anti-IgE therapy in two patients with refractory forme fruste of Churg-Strauss syndrome. Thorax 2008, 63:747-748.
116. Ruppert A.M., Averous G., Stanciu D., Deroide N., Riehm S., Poindron V., et al. Development of Churg-Strauss syndrome with controlled asthma during omalizumab treatment. J Allergy Clin Immunol 2008, 121:253-254.
117. Winchester D.E., Jacob A., Murphy T. Omalizumab for asthma. N Engl J Med 2006, 355:1281-1282.
118. Sanchez J., Ramirez R., Diez S., Sus S., Echenique A., Olivares M., et al. Omalizumab beyond asthma. Allergol Immunopathol (Madr) 2012, 40:306-315.